PACIRA BIOSCIENCES INC (PCRX) — insider trading
Health Care · NASDAQ
PACIRA BIOSCIENCES INC (PCRX) has 33 reported SEC Form 4 insider transactions in our data, including 7 open-market sales among the most recent 33 (latest 2026-08-17).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-08-17 | SLONIN JONATHAN | Officer (Chief Medical Officer) | Open-market sale | 3,040 | $23.23 | $70.6K | Form 4 |
| 2026-06-11 | RIKER LAUREN | Officer (Senior Vice President, Finance) | Open-market sale | 6,115 | $23.50 | $143.7K | Form 4 |
| 2026-06-10 | Brege Laura | Director | Grant / award / vesting (derivative) | 10,891 | — | $0 | Form 4 |
| 2026-06-10 | Brege Laura | Director | Grant / award / vesting | 6,405 | — | $0 | Form 4 |
| 2026-06-10 | Froimson Mark | Director | Grant / award / vesting (derivative) | 10,891 | — | $0 | Form 4 |
| 2026-06-10 | Froimson Mark | Director | Grant / award / vesting | 6,405 | — | $0 | Form 4 |
| 2026-06-10 | BIGAL MARCELO | Director | Grant / award / vesting (derivative) | 10,891 | — | $0 | Form 4 |
| 2026-06-10 | BIGAL MARCELO | Director | Grant / award / vesting | 6,405 | — | $0 | Form 4 |
| 2026-06-10 | YANG MICHAEL J. | Director | Grant / award / vesting (derivative) | 10,891 | — | $0 | Form 4 |
| 2026-06-10 | YANG MICHAEL J. | Director | Grant / award / vesting | 6,405 | — | $0 | Form 4 |
| 2026-06-10 | Young Alethia | Director | Grant / award / vesting (derivative) | 10,891 | — | $0 | Form 4 |
| 2026-06-10 | Young Alethia | Director | Grant / award / vesting | 6,405 | — | $0 | Form 4 |
| 2026-06-10 | WIGGANS THOMAS G | Director | Grant / award / vesting (derivative) | 32,675 | — | $0 | Form 4 |
| 2026-06-10 | CHRISTIE CHRISTOPHER | Director | Grant / award / vesting (derivative) | 10,891 | — | $0 | Form 4 |
| 2026-06-10 | CHRISTIE CHRISTOPHER | Director | Grant / award / vesting | 6,405 | — | $0 | Form 4 |
| 2026-06-10 | Hirawat Samit | Director | Grant / award / vesting (derivative) | 10,891 | — | $0 | Form 4 |
| 2026-06-10 | Hirawat Samit | Director | Grant / award / vesting | 6,405 | — | $0 | Form 4 |
| 2026-06-04 | WILLIAMS KRISTEN | Officer (Chief Administrative Officer) | Open-market sale | 10,259 | $22.27 | $228.5K | Form 4 |
| 2026-06-03 | WILLIAMS KRISTEN | Officer (Chief Administrative Officer) | Shares withheld for taxes / exercise cost | 8,528 | $22.32 | $190.3K | Form 4 |
| 2026-06-03 | SLONIN JONATHAN | Officer (Chief Medical Officer) | Shares withheld for taxes / exercise cost | 4,728 | $22.32 | $105.5K | Form 4 |
| 2026-06-03 | RIKER LAUREN | Officer (Senior Vice President, Finance) | Shares withheld for taxes / exercise cost | 3,187 | $22.32 | $71.1K | Form 4 |
| 2026-04-23 | Cross Shawn | Officer (Chief Financial Officer) | Option exercise / conversion (derivative) | 12,941 | — | $0 | Form 4 |
| 2026-04-23 | Cross Shawn | Officer (Chief Financial Officer) | Open-market sale | 12,941 | $25.16 | $325.6K | Form 4 |
| 2026-04-23 | Cross Shawn | Officer (Chief Financial Officer) | Option exercise / conversion | 12,941 | $16.45 | $212.9K | Form 4 |
| 2026-04-22 | Cross Shawn | Officer (Chief Financial Officer) | Option exercise / conversion (derivative) | 1,500 | — | $0 | Form 4 |
| 2026-04-22 | Cross Shawn | Officer (Chief Financial Officer) | Open-market sale | 1,500 | $25.01 | $37.5K | Form 4 |
| 2026-04-22 | Cross Shawn | Officer (Chief Financial Officer) | Option exercise / conversion | 1,500 | $16.45 | $24.7K | Form 4 |
| 2026-04-21 | Cross Shawn | Officer (Chief Financial Officer) | Option exercise / conversion (derivative) | 2,845 | — | $0 | Form 4 |
| 2026-04-21 | Cross Shawn | Officer (Chief Financial Officer) | Open-market sale | 2,845 | $25.01 | $71.2K | Form 4 |
| 2026-04-21 | Cross Shawn | Officer (Chief Financial Officer) | Option exercise / conversion | 2,845 | $16.45 | $46.8K | Form 4 |
| 2026-04-20 | Cross Shawn | Officer (Chief Financial Officer) | Option exercise / conversion (derivative) | 7,714 | — | $0 | Form 4 |
| 2026-04-20 | Cross Shawn | Officer (Chief Financial Officer) | Open-market sale | 7,714 | $25.14 | $193.9K | Form 4 |
| 2026-04-20 | Cross Shawn | Officer (Chief Financial Officer) | Option exercise / conversion | 7,714 | $16.45 | $126.9K | Form 4 |
Ask the chat about PCRX's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: PACIRA BIOSCIENCES INC (PCRX).
Last updated 2026-08-17 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.